drugset / Trial / NCT05039268
3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Non-randomizedSequentialOpen-labelTreatment
Summary
Phase 2 open label trial to investigate the safety and potentially efficacy of 3K3A-APC in patients with Amyotrophic Lateral Sclerosis (ALS).
Timeline
- Start
- 2021-11-25
- Primary completion
- 2022-09-12
- Completion
- 2022-09-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | 3K3A-APC | Protein / enzyme biologic | 15 mg | Intravenous |
| Comparator | 3K3A-APC | Protein / enzyme biologic | 30 mg | Intravenous |